FDA Greenlights First Gene Therapy for Genetic Hearing Loss

The Food and Drug Administration (FDA) has approved Otarmeni, a groundbreaking gene therapy developed by Regeneron, specifically for genetic hearing loss. This marks the first gene therapy aimed at addressing this condition caused by mutations in the OTOF gene, impacting a small population of newborns in the United States. Approximately 50 infants are diagnosed with this rare type of hearing loss each year.

Key Details of Otarmeni’s Approval

Regeneron’s Otarmeni received FDA approval through the Commissioner’s National Priority Voucher program, designed to expedite drug reviews. Dr. Eliot Shearer, a pediatric otolaryngologist involved in the clinical trials, stated that this treatment could significantly change the lives of families with affected children.

• Current Treatment Options: The main alternative for children with genetic deafness has been cochlear implants.
• Gene Therapy Benefits: Unlike cochlear implants, which may diminish sound quality, Otarmeni provides continuous hearing and does not depend on battery power.

Mechanism of Action

Otarmeni functions by correcting the mutation in the OTOF gene. This gene is essential for instructing the body to produce otoferlin, a protein critical for transmitting sound signals from cochlear cells to the auditory nerve. Without adequate otoferlin, auditory signals cannot reach the brain, resulting in hearing loss.

Clinical Trial Insights

The approval followed a clinical trial involving 20 children with the OTOF mutation who were administered a single dose of Otarmeni. Results showed improvement in hearing for 16 out of 20 participants, with five children achieving the ability to detect whispers.

However, some side effects were noted, including:

• Infection or inflammation of the middle ear
• Nausea
• Vomiting
• Dizziness

Cost and Accessibility

In a noteworthy initiative, Regeneron has pledged to provide Otarmeni free of charge to U.S. patients. However, the costs associated with administering the therapy will not be covered by the manufacturer. The delivery procedure requires general anesthesia and parallels that of cochlear implant surgeries.

The drug, at this point, is not available outside the United States, and Regeneron has not established a list price for international patients seeking treatment. Gene therapy can typically reach exorbitant prices, often in the millions of dollars.

Sarah Emond, president and CEO of the Institute for Clinical and Economic Review, praised Regeneron for its decision to offer the therapy without charge to the health system, suggesting it as a model for improving patient access to innovative treatments.